Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study

Journal of the American College of Cardiology

Volumn 45, Issue 12, 2005, Pages 1925-1931

  Pfützner, Andreas ^a,b,f   Marx, Nikolaus ^c   Lübben, Georg ^d   Langenfeld, Matthias ^a   Walcher, Daniel ^c   Konrad, Thomas ^e   Forst, Thomas ^a  

^a IKFE   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d Takeda Pharma GmbH   (Germany)

^e Institute for Metabolic Research   (Germany)

^f Institute for Clinical Research and Development   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CD40 LIGAND; FIBRINOGEN; GELATINASE B; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE-PHASE PROTEINS; AGED; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BLOOD GLUCOSE; CAROTID ARTERIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TUNICA INTIMA; TUNICA MEDIA;

EID: 20444495375     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.03.041     Document Type: Article

References (38)

1. B. Howard, B. Rodriguez, P. Bennet Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology Circulation 105 2002 e132 e137
2. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
3. R. Ross Artherosclerosis an inflammatory disease N Engl J Med 340 1999 115 126
4. P.M. Ridker Evaluating novel cardiovascular risk factors can we better predict heart attacks? Ann Intern Med 130 1999 933 937
5. P.M. Ridker, C.H. Hennekens, J.E. Buring, N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
6. J.T. Willerson, P.M. Ridker Inflammation as cardiovascular risk factor Circulation 109 Suppl 1 2004 II2 II10
7. P. Aukrust, F. Muller, T. Ueland Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes Circulation 100 1999 614 620
8. F. Cipollone, A. Mezzetti, E. Porreca Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia effects of statin therapy Circulation 106 2002 399 402
9. A.K. Death, E.J. Fisher, K.C. McGrath, D.K. Yue High glucose alters matrix metalloproteinase expression in two key vascular cells potential impact on atherosclerosis in diabetes Atherosclerosis 168 2003 263 269
10. P. Ferroni, S. Basili, F. Martini Serum metalloproteinase 9 levels in patients with coronary artery disease a novel marker of inflammation J Investig Med 51 2003 295 300
11. S. Blankenberg, H.J. Rupprecht, O. Poirier Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease Circulation 107 2003 1579 1585
12. N. Varo, D. Vicent, P. Libby Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients a novel target of thiazolidinediones Circulation 107 2003 2664 2669
13. V. Pasceri, J.S. Cheng, J.T. Willerson, E.T. Yeh, J. Chang Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs Circulation 103 2001 2531 2534
14. C. Jiang, A.T. Ting, B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
15. N. Marx, G. Sukhova, C. Murphy, P. Libby, J. Plutzky Macrophages in human atheroma contain PPARgamma differentiation-dependent peroxisomal proliferators-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro Am J Pathol 153 1998 17 23
16. H. Ito, A. Nakano, M. Kinoshita, A. Matsumori Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model Lab Invest 83 2003 1715 1721
17. P. Mohanty, A. Aljada, H. Ghanim Evidence for a potent antiinflammatory effect of rosiglitazone J Clin Endocrinol Metab 89 2004 2728 2735
18. N. Marx, J. Froehlich, L. Siam Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease Arterioscler Thromb Vasc Biol 23 2003 283 288
19. N. Marx, A. Imhof, J. Froehlich Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease Circulation 107 2003 1954 1957
20. R. Tang, M. Hennig, B. Thomasson Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness the European Lacidipine Study of Atherosclerosis (ELSA) J Hypertens 18 2000 197 201
21. M.L. Bots, G.W. Evans, W.A. Riley, D.E. Grobbee Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view Stroke 34 2003 2985 2994
22. M. Tan, D. Johns, G. Gonzalez Galvez GLAD Study Group Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus a multicenter, randomized, double-blind, parallel-group trial Clin Ther 26 2004 680 693
23. M.H. Tan, D. Johns, J. Strand Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes Diabet Med 21 2004 859 866
24. G. Derosa, A.F. Cicero, A. Gaddi Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial Clin Ther 26 2004 744 754
25. A.B. King, D.U. Armstrong Lipid response to pioglitazone in diabetic patients clinical observations from a retrospective chart review Diabetes Technol Ther 4 2002 145 151
26. M.F. Saad, S. Greco, K. Osei Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm Diabetes Care 27 2004 1324 1329
27. J. Tordjman, G. Chauvet, J. Quette, E.G. Beale, C. Forest, B. Antoine Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells J Biol Chem 278 2003 18785 18790
28. S.M. Haffner, A.S. Greenberg, W.M. Weston, H. Chen, K. Williams, M.I. Freed Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 106 2002 679 684
29. N. Satoh, Y. Ogawa, T. Usui Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect Diabetes Care 26 2003 2493 2499
30. K.H. Han, O. Quehenberger Ligands for peroxisome proliferator-activated receptor inhibit monocyte CCR2 expression stimulated by plasma lipoproteins Trends Cardiovasc Med 10 2000 209 216
31. M. Ishibashi, K. Egashira, K. Hiasa Anti-inflammatory and anti-arteriosclerotic effects of pioglitazone Hypertension 40 2002 687 693
32. K. Kato, H. Satoh, Y. Endo Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells a possible role for PPARgamma in endothelial function Biochem Biophys Res Commun 258 1999 431 435
33. A. Zirlik, A. Leugers, J. Lohrmann Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones Thromb Haemost 91 2004 674 682
34. G. He, S.B. Pedersen, J.M. Bruun, A.S. Lihn, B. Richelsen Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro Horm Metab Res 35 2003 18 23
35. A. Osman, J. Otero, A. Brizolara Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes Am Heart J 147 2004 e23
36. M.L. Bots, A.W. Hoes, P.J. Koudstaal, A. Hofman, D.E. Grobbee Common carotid intima-media thickness and risk of stroke and myocardial infarction the Rotterdam study Circulation 96 1997 1432 1437
37. P.J. Touboul, A. Elbaz, C. Koller The GENIC Investigators Common carotid artery intima-media thickness and brain infarction the Etude du Profil Genetique de l'Infarctus Cerebral (GENIC) case-control study Circulation 102 2000 313 318
38. B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, A. Skene PROactive Study Group The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients Diabetes Care 27 2004 1647 1653